RxDoctor Payments Data

Fritz Allen, MD

Ophthalmology · Kensington, MDNPI 1548332042

Payments from drug & device makers

$3,226in general payments, 2019–2025

Across 127 payments — averaging $25.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • NEW World Medical,inc.$405
  • Mallinckrodt Hospital Products Inc.$397
  • Mallinckrodt Enterprises LLC$262
  • Alcon$129
  • Aerie Pharmaceuticals, Inc.$108
  • plus $584 from 15 others

What the payments were for

  • Food & beverage$2,99393%
  • Education$2347%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,226 in reported general payments places this provider in the 65th percentile of 493 ophthalmology providers in Maryland.

See all ophthalmology providers in Maryland

Medicare billing

Part B allowed, 2024
$127,423
Medicare patients
517
Services billed
1,425

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine59$92,004
XiidraLifitegrast12$24,449
LumiganBimatoprost34$22,174
CombiganBrimonidine Tartrate/Timolol23$13,508
Cyclosporine23$8,096
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol25$5,892
Latanoprost460$5,039
Brimonidine Tartrate68$3,844
Timolol Maleate134$3,704
Brinzolamide14$3,361
Timolol MaleateTimolol Maleate/Pf12$3,038
Prednisolone Acetate28$1,124
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat47$892
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha36$417
Dorzolamide Hcl11$233

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$1,342$127,687116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 493 ophthalmology providers in Maryland.

Other ophthalmology in Kensington

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →